Tesamorelin treats visceral fat in HIV lipodystrophy - not general weight loss

What tesamorelin is actually approved to do

Tesamorelin is sold in the United States as Egrifta (including Egrifta WR and Egrifta SV formulations). It is a synthetic analog of growth hormone-releasing factor. The FDA-approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. That is a complication of HIV and some antiretroviral regimens, not a synonym for 'wanting a smaller waist.'

This article is educational, not medical advice. Beema Health does not offer tesamorelin. Wellness marketing that calls tesamorelin a weight-loss peptide skips the limitation of use printed in the label: it is not indicated for weight-loss management and has a weight-neutral effect on the scale.

Why tesamorelin is not in the GLP-1 family

GLP-1 receptor agonists act on incretin pathways that reduce appetite and slow gastric emptying. Tesamorelin acts on the pituitary to increase endogenous growth hormone, which then raises IGF-1. Those are different hormones, different receptors, and different trial endpoints. Grouping tesamorelin with semaglutide because both are 'injections about fat' is biologically false.

People searching GLP-1 peptides for weight loss should not be steered toward tesamorelin as a substitute. If the clinical goal is chronic weight management, the evidence base that regulators and obesity guidelines discuss is incretin-based therapy, lifestyle support, and sometimes other labeled obesity medicines - not HIV lipodystrophy therapy.

• Tesamorelin: GHRH analog for HIV-associated visceral fat, daily injection, weight-neutral on label
• Semaglutide/tirzepatide class: incretin agonists studied for percent body-weight change
• Beema offering: neither tesamorelin nor branded Egrifta

Limitations of use you will not see in a peptide ad

The Egrifta WR prescribing information is explicit. Long-term cardiovascular safety has not been established. Clinicians are told to weigh continuation if visceral fat does not clearly improve. There are no data that tesamorelin improves adherence to antiretroviral therapy. Formulations differ in milligram strength, reconstitution, and storage; Egrifta WR and Egrifta SV are not substitutable.

Glucose monitoring matters because growth-hormone axis stimulation can worsen hyperglycemia. People without HIV lipodystrophy who buy 'tesamorelin for fat loss' from a research shop take on those endocrine risks without the labeled benefit that justified approval.

Prescription medicine versus research vials

Egrifta is a prescription product dispensed by licensed pharmacies for an approved (or carefully justified off-label) use. Vials marketed as research tesamorelin are not that product. Beema will not help anyone purchase unlabeled peptides. GLP-1-class weight-loss care, when offered here, is also prescription-only after a licensed provider reviews intake - never a cart checkout.

If you actually have HIV-associated lipodystrophy

That diagnosis belongs with an HIV clinician who knows your antiretroviral regimen, glucose, and cancer screening. Tesamorelin, if considered, is their conversation, not a telehealth weight-loss program's default menu. Beema's questionnaire is built for medical weight loss with compounded GLP-1-class options, not for HIV metabolic complications.

What Beema Health offers instead

Adults in all 50 U.S. states can complete Beema's online intake. A licensed provider may prescribe compounded semaglutide or compounded tirzepatide when legally available and clinically appropriate. Compounded semaglutide is not FDA-approved. Compounded tirzepatide is not FDA-approved. Prescribing is never guaranteed.

If tesamorelin appeared in your search results next to retatrutide or sermorelin, treat that as a merchandising bundle, not a medical category. Read the sermorelin article next if you want another GHRH analog's true history, then return to GLP-1 education if weight management is the goal.

Frequently asked questions

Sources

1. [1] EGRIFTA WR (tesamorelin) for injection. U.S. prescribing information. Indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Limitation: not indicated for weight-loss management.
2. [2] EGRIFTA (tesamorelin) original U.S. label (2010): same core indication and weight-neutral limitation of use.
3. [3] U.S. Food and Drug Administration. Tesamorelin orphan designation history for HIV-associated lipodystrophy.
4. [4] NIDDK. Prescription medications to treat overweight and obesity (GLP-1-class options are listed separately from HIV lipodystrophy therapies).